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Current systemic therapies have little curative beneﬁt for synovial sarcoma. Histone deacetylase (HDAC) inhibitors and the heat
shock protein 90 (Hsp90) inhibitor 17-AAG have recently been shown to inhibit synovial sarcoma in preclinical models. We tested
combinations of 17-AAG with the HDAC inhibitor MS-275 for synergism by proliferation and apoptosis assays. The combination
was found to be synergistic at multiple time points in two synovial sarcoma cell lines. Previous studies have shown that HDAC
inhibitors not only induce cell death but also activate the survival pathway NF-κB, potentially limiting therapeutic beneﬁt. As 17-
AAGinhibitsactivatorsofNF-κB,wetestedif17-AAGsynergizeswithMS-275throughabrogatingNF-κBactivation.Inourassays,
adding 17-AAG blocks NF-κB activation by MS-275 and siRNA directed against histone deacetylase 3 (HDAC3) recapitulates the
eﬀects of MS-275. Additionally, we ﬁnd that the NF-κB inhibitor BAY 11-7085 synergizes with MS-275. We conclude that agents
inhibiting NF-κB synergize with HDAC inhibitors against synovial sarcoma.
Copyright © 2009 Anne Nguyen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Synovial sarcoma is an aggressive malignancy, typically
occurring in the soft tissues of young adults, comprising
up to 10% of adult sarcomas in some series [1]. Current
therapies for synovial sarcoma involve surgical resection
followed by either radiotherapy and/or chemotherapy (such
as doxorubicin) [2], with 5-year metastasis-free survival
rates between 48% and 68% [3–5]. The chromosomal
translocation t(X;18)(p11.2;q11.2), resulting in an SYT-SSX
fusion oncoprotein, is demonstrable in almost all cases [1],
but its molecular function is unclear, and it is not directly
targeted by established drugs.
The heat shock protein 90 (Hsp90) inhibitor 17-
(allylamino)-17-demethoxygeldanamycin (17-AAG) is eﬀec-
tive against synovial sarcoma in vitro [6]. Hsp90 is a
chaperone assisting in the folding of client proteins such
as CDK-4, Raf-1 [7], HER2 [8], mutant p53 [9], Bcr-Abl
[10], IKK [11], and RIP [12] which play important roles
in oncogenic cell growth, division, and survival. Hsp90
inhibition results in degradation of its client proteins,
inhibition of tumor growth, induction of diﬀerentiation and
activation of apoptosis [13]. The Hsp90 inhibitor 17-AAG
hascompletedphaseIclinicaltrials[14]andisin phaseIIfor
several malignancies including metastatic melanoma, breast
cancer, and ovarian cancer [15].
The HDAC inhibitor romidepsin (FK228; depsipeptide)
has also been demonstrated to be eﬀective against synovial
sarcoma models, where nanomolar levels cause histone
acetylation, inhibition of growth, and invasion in cell
cultures and mouse xenografts [16]. We have conﬁrmed
these ﬁndings using the HDAC inhibitors trichostatin A,
romidepsin, and MS-275 on synovial sarcoma cell lines
[17, 18]. HDAC activity acts within transcription factor
complexes to suppress transcription at target loci, including
tumor suppressors and genes driving diﬀerentiation [19, 20]
by decreasing net acetylation of histones. HDAC inhibitors
lead to acetylation of several other proteins, including p53
[21], NF-κB[ 22], and Hsp90 [23] which have roles in
cellular growth, survival, and protein folding. Several HDAC
inhibitors (including MS-275; an orally bioavailable agent)
are currently involved in phase I and II clinical trials of2 Sarcoma
malignancies including leukemias, lymphomas, melanomas,
and refractory solid tumors [24]. In synovial sarcoma,
Ito et al. have shown that the SYT partner of the SYT-
SSX fusion oncoprotein interacts with a HDAC complex,
providing a mechanism for speciﬁc activity of HDAC
inhibitors in this disease [25]. Furthermore, we have recently
shown that HDAC inhibitor action reverses polycomb-
mediated epigenetic suppression of SYT-SSX target genes
[26].
The evidence that both 17-AAG and HDAC inhibitors
are individually eﬀective against synovial sarcoma raises the
question of whether combinations would be synergistic. To
date, synergy studies using Hsp90 inhibitors and various
HDAC inhibitors (SAHA, sodium butyrate, and cinnamic
hydroxamic acid analog) have shown positive results in
variety of human leukemia cells [10, 27, 28]. However,
in other models, the combination appears antagonistic;
Huang et al. reported that pretreatment with the Hsp90
inhibitor geldanamycin before addition of trichostatin A
averted death in COS-7 cells [29], and Yang et al. found that
coadministration of romidepsin with 17-AAG had neither
synergistic nor additive eﬀects on RUNX1-ETO levels in
Kasumi-1 leukemic cells [30]. As each type of agents is
individually eﬀective against synovial sarcoma cells, and
synergy could potentially be of great beneﬁt to patients, in
this study, we seek to test combinations of 17-AAG with
the HDAC inhibitor MS-275 for eﬃcacy against synovial
sarcoma.
A possible mechanism for synergy between HDAC and
Hsp90inhibitorsinvolveseﬀectsonthesurvivalpathwayNF-
κB. NF-κB is a transcription factor constitutively activated
in many cancer models [31], wherein it confers resistance to
apoptosis and promotes cell survival [32], angiogenesis, and
invasion [33]. Expression proﬁling studies by us and others
have shown that RIPK4, an activator of NF-κB[ 34], is highly
expressed within synovial sarcoma primary tumor samples
[35]. HDAC3 regulates acetylation of the NF-κB subunit
RelA,therebyreducingitstranscriptionalactivity[22].Other
studies have conﬁrmed that HDAC inhibitors induce NF-
κBa c t i v i t y ;a ne ﬀect which diminishes the lethality of these
drugs against lung cancer cell lines [36]. In contrast, 17-AAG
has been shown to be an eﬀective inhibitor of the NF-κB
pathway [12]. In this work, we also investigate if 17-AAG can
synergize with HDAC inhibitors by reducing the activation
of NF-κB.
2.MaterialsandMethods
2.1. Reagents. 17-AAG was provided under the terms of
a materials transfer agreement (MTA) with the Devel-
opmental Therapeutics Branch of the National Cancer
Institute (Bethesda, Md, USA) through Kosan Biosciences
(Hayward, Calif, USA). MS-275 was provided under the
terms of an MTA by Schering AG (Berlin, Germany)
throughBerlexPharmaceuticals(Montville,NJ,USA).RPMI
1640, fetal bovine serum, and trypsin were purchased from
Life Technologies (Invitrogen, Mississauga, ON, Canada).
siRNA targeting HDAC3 was obtained from Santa Cruz
Biotechnology (Santa Cruz, Calif, USA), catalog number
sc-35538; a 50ng dose was conﬁrmed by western blot to
knock down HDAC3 in synovial sarcoma cells by 71% at
24 hours relative to scrambled siRNA control. BAY 11-
7085 was purchased from Calbiochem (San Diego, Calif,
USA). The pNF-κB-Luc plasmid, containing the ﬁreﬂy
luciferase (luc) gene from photinus pyralis and multiple
copies of the NF-κB consensus sequence fused to a TATA-like
promoter region from the herpes simplex virus thymidine
kinase promoter, was from Clontech (Mountain View, Calif,
USA).
2.2. Monolayer Cell Culture and Drug Eﬀect Assays. The
biphasic synovial sarcoma cell line SYO-1 and the monopha-
sic human cell line Fuji were kindly provided by Akira
Kawai (National Cancer Centre Hospital, Tokyo, Japan),
and Kazuo Nagashima (Hokkaido University School of
Medicine, Sapporo, Japan), respectively [37, 38]. MTT
proliferation and annexin V-FITC/propidium iodide ﬂow
cytometry assays were performed as previously described
[6].
2.3. Protein Quantiﬁcation. Sample protein concentrations
were determined by bicinchoninic acid assay (BCA Protein
Assay kit, Pierce, Rockford, Ill, USA) as per manufacturer’s
instructions. Samples were measured for absorbance at 562
nm in a PowerWaveX enzyme-linked immunoabsorbent
assay plate reader from Bio-Tek Instruments (Winooski, Vt,
USA).
2.4. Lysate Preparation. Total cellular extracts were pre-
pared in lysis buﬀer (10mM Tris pH 7.5, 1mM EGTA,
150mM NaCl, 1% Triton X-100, 0.5% Nonidet P-40, 1mM
Na3VO4, and 1mM PMSF) from 4 × 105 cells, incubated
on ice for 20 minutes, and centrifuged at 10000g to
remove cellular debris. Puriﬁed nuclear and cytoplasmic
extracts were prepared by using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents kit (Pierce, Rockford, Ill,
USA).
2.5. Immunoblot Analysis. Mouse α-acetyl lysine and rabbit
α-p65 were purchased from Abcam (Cambridge, Mass,
USA), mouse α-IκBα from Cell Signaling (Beverly, Mass,
USA), and rabbit α-p85 from Upstate Millipore (Char-
lottesville, Va, USA). Goat α-rabbit HRP and goat α-mouse
HRP secondary antibodies were purchased from Pierce
Biotechnology (Rockford, Ill, USA). Protein samples were
loaded onto a 10% SDS polyacrylamide gel. Western blotting
of the samples was done according to standard procedures.
Membranes were incubated in 1mL of SuperSignal West
Femto Luminol/Enhancer Solution with 1mL Stable Per-
oxide Buﬀer from Pierce (Rockford, Ill, USA) at room
temperature for 2 minutes and exposed onto photographic
ﬁlm.
2.6. Luciferase Assays. SYO-1 cells were plated onto 24-well
plates at 4 × 104 cells/well. SYO-1 cells were transfected
with 0.3μg of plasmid/well using FuGENE 6 Transfection
reagent (Roche Applied Science, Indianapolis, Ind, USA) asSarcoma 3
Table 1: Comparison of IC50 values at 24- and 48 hour Timepoints
for MS-275 and 17-AAG as single agents and in combination using
MTT assay.
Timepoint (hrs)
IC50 average
MS-275 17-AAG Combination (μM)
(μM) (μM) MS-275 17-AAG
24 4.5 2.1 0.6 0.25
48 0.56 0.32 0.3 0.12
per manufacturer’s instructions, and they were treated the
following day. After 24 hours of treatment, cells were washed
and 100μL of ice cold 1× Passive Lysis Buﬀer from the Dual-
Luciferase Reporter Assay System kit (Promega, Madison,
Wis, USA) was added. Cells were incubated shaking for
20 minutes at room temperature. Samples were aliquoted
3t i m e sa t2 0 μL/well to a luciferase plate and twice at
10μL/well to a 96-well plate for protein quantiﬁcation.
Samples were injected with 50μL/well of LARII from the
kit and read on an EG&G Berthold microplate luminometer
96V (Germany). Samples were normalized to total protein
concentration, and average values were compared to vehicle
control set to 1.
2.7. Synergism Analysis. Synergy was quantiﬁed according
to the protocol published by Chou and Talalay [39]. The
log of the fraction aﬀected/fraction unaﬀected was plotted
as a function of the log of the dose to determine the IC50
fromtheequationlog(fa/fu) =mlog(D) −mlog(IC50).Dose
responses of drugs in combination were tested at a ﬁxed
ratio.Combinationindex(CI)valueswereobtainedfromthe
equation CIx = Dc1x/D1x + Dc2x/D2x + Dc1xDc2x/D1xD2x,
where Dc1x is dose of drug 1 in combination required
for achieving x percent of cell inviability. Combination
index values below 1 are indication of synergism, near 1 of
additivity, and greater than 1 of antagonism. MTT and NF-
κB luciferase reporter experiments using the drugs as single
agents and in combination were done in triplicates, and all
experiments to determine synergism were repeated at least
once. Annexin V-FITC apoptosis assays and western blotting
assays were likewise repeated once. Statistical analyses on
replicates were performed by calculating 95% conﬁdence
intervals.
3. Results
3.1. 17-AAG Synergizes with MS-275 against Synovial Sar-
coma in vitro. To determine if the combination of Hsp90
inhibitors and HDAC inhibitors are able to synergize on
synovial sarcoma, an in vitro MTT cell proliferation assay
was performed on the synovial sarcoma cell lines SYO-
1 and Fuji using the Hsp90 inhibitor 17-AAG and the
HDAC inhibitor MS-275. Cells were grown in monolayer
culture and exposed to varying concentrations of each agent
alone to determine IC50 values. Both agents are eﬀective
at reducing cell proliferation on both synovial sarcoma
cell lines in a dose- and time-dependent manner, with
IC50 values shown in Table 1 for SYO-1. Both are more
eﬀective at inhibiting the growth of the synovial sarcoma
cell line SYO-1 than equimolar doxorubicin. Whereas 1μM
of doxorubicin reduces the number of viable SYO-1 cells
by 7%, 1μM of 17-AAG and 1μM of MS-275 reduce the
number of cells by 42% and 11%, respectively. Based on
these results, the cell lines were then treated in combinations
at multiples of a set ratio of 2 parts of 17-AAG to 5
parts of MS-275 and tested for cell proliferation. 17-
AAG and MS-275 in combination showed much greater
eﬀectiveness at lower doses for reducing cell proliferation
on both synovial sarcoma cell lines, in a dose- and time-
dependent manner (Figure 1), than either agent alone,
with combination index values below 1, indicating syn-
ergy.
To conﬁrm synergy, the Annexin V-FITC apoptosis assay
was also used at 24 hours and 48 hours. Eﬃcacy of 17-
AAG and MS-275 as single agents on synovial sarcoma
was conﬁrmed by these assays at all time points in a
time- and dose-dependent manner (data not shown). In
combination at a set ratio of 2 parts of 17-AAG to 5 parts
of MS-275, greater apoptosis was observed at lower doses,
again indicating drug synergy. Combination index values
were as low as 0.11 and 0.07 for 24 hours and 48 hours,
respectively.
3.2.MechanismofSynergyInvolves17-AAGAbrogationofMS-
275-Induced NF-κBA c t i v a t i o n . The IκBα complex acts as an
NF-κB inhibitor by binding to NF-κB dimers, shuttling them
to the cytoplasm, and retaining them there. IκBα levels are
inverselyproportionaltoNF-κBactivation.Asaninhibitorof
theNF-κBpathway,ithasbeenfoundthat17-AAGiscapable
of maintaining levels of IκBα [40]. To explore the possibility
of synergy through a mechanism involving NF-κB, protein
levelsofIκBαweremeasuredinresponseto17-AAGandMS-
275 individually and in combination with synovial sarcoma
cells. By western blot, IκBα levels decrease with MS-275
treatmentinadose-dependentmanner,indicating activation
oftheNF-κBpath wa y;aneﬀectwhichisabrogatedbyadding
17-AAG (Figure 2).
NF-κB activation requires relocation of NF-κBh e t -
erodimers from the cytoplasm to the nucleus before it can
mediate its transcriptional eﬀectson cellsurvival.In synovial
sarcoma cells, we ﬁnd that nuclear levels of the RelA subunit
of NF-κB increase during MS-275 treatment, but decrease in
the presence of 17-AAG as a single agent or in combination
with MS-275 (Figure 3).
Finally, we looked at the transcriptional potential of
NF-κB following treatment with these drugs using an
NF-κBl u c i f e r a s er e p o r t e r( Figure 4). MS-275 dramati-
cally increases NF-κB transcriptional activity (almost 20-
fold at higher doses), whereas 17-AAG as a single agent
decreases transcriptional activity. In the combination, the
17-AAG eﬀect predominates, and there is a net inhi-
bition of NF-κB transcriptional activity. Similar results4 Sarcoma
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Figure 1: Eﬀect of 17-AAG and MS-275 in combination on SYO-1 synovial sarcoma monolayer cultures. Cell survival at (a) 24 hours and (b) 48
hours for drugs combined at a set ratio of 2 parts 17-AAG to 5 parts MS-275. MTT cell proliferation assays were performed for the indicated
doses, and survival is plotted relative to vehicle control. Corresponding combination indices are shown for (c) 24 and (d) 48 hours, where
values below 1 indicate synergistic drug interactions. Error bars represent 95% conﬁdence intervals. Combination indices were calculated
using the Chou and Talalay Median Dose Method (not applicable at low doses where eﬀective cell killing relative to control cell death was
not observed).
were found with Fuji synovial sarcoma cells (data not
shown).
3.3. Histone Deacetylase 3 (HDAC3) siRNA Knockdown
Has Similar Eﬀects to MS-275. The RelA subunit of NF-
κB is acetylated by HDAC3 [22], reducing its ability
to interact with its inhibitor IκBα. All HDAC inhibitors
previously shown to killsynovial sarcoma cells [16–18]
include HDAC3 among their speciﬁc targets. Therefore,
we hypothesized that our observations on MS-275 (killing
synovial sarcoma cells, but activating NF-κB in a manner
which can be blocked with 17-AAG) might be explained
speciﬁcally by HDAC3 inhibition. We ﬁnd that siRNA
directed against HDAC3 kills SYO-1 cells, whereas the
scrambled siRNA control does not (Figure 5(a)). Further-
more, HDAC3 knockdown induces RelA nuclear translo-
cation, and this eﬀect is largely abrogated by adding
17-AAG (Figure 5(b)). Thus, the same eﬀects on cellSarcoma 5
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Figure 2: Dose Response of IκBα. Immuunoblots and quantitation of IκBα levels after treatment with (a) MS-275, (b) 17-AAG and (c)
Combination. Following 24 hour treatment total lysates were prepared and quantiﬁed. 10μg of lysate was run on an SDS-page gel. By
immunoblotting, IκBα and p85 (as a loading control) were detected using α-IκBα and α-p85 antibodies. Protein levels following treatment
are compared to vehicle control which is set at 1.00.
survival and NF-κB activation are seen with HDAC3
siRNA knockdown as with the HDAC inhibitor drug MS-
275.
3.4. MS-275 Synergizes with NF-κB Inhibitors. The com-
pound BAY 11-7085 is a commercially available inhibitor
of NF-κB[ 41]. In our NF-κB luciferase reporter assay
system, BAY 11-7085 strongly represses NF-κBa c t i v i t y
in SYO-1 cells with an IC50 of 4.9μMa t2 4h o u r s .
The combination of BAY 11-7085 and MS-275 showed
combination index values as low as 0.26 for 24 hours
and 0.25 for 48 hours, indicating synergism between
this NF-κB inhibitor and the HDAC inhibitor MS-275
(Table 2).6 Sarcoma
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Figure 3: Dose Response of RelA. Immunoblots and quantitation of nuclear RelA after treatment with (a) MS-275, (b ) 17-AAG and (c)
Combination. Following 24 hour treatment, nuclear and cytoplasmic extracts were prepared and quantiﬁed. 15μg were run on an SDS-page
gel. Using immunoblotting techiniques, RelA and p85 (as a loading control) were detected using α-RelA and α-p85 antibodies. Protein levels
following treatment are compared to vehicle control which is set at 1.00.
4. Discussion
In current clinical practice, available systemic therapies
for synovial sarcoma have limited eﬀectiveness and have
not been deﬁnitively proven to increase cure rates. Recent
research building on gene expression proﬁling data has
identiﬁed several promising agents active against synovial
sarcoma [42]. 17-AAG is eﬀective against synovial sarcoma
preclinical models, but clinical trials in other tumors have
shown some toxicity at higher doses including evidence of
liver toxicity, optic neuritis, dyspnea, fatigue, nausea, vomit-
ing, anorexia, diarrhea, anemia, and low grade fever [43, 44].
Similarly, in high doses, MS-275 has shown such toxicity
as nausea, vomiting, anorexia, fatigue, hypoalbuminemia,Sarcoma 7
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Figure 4: Transcriptional activation of NF-κB luciferase reporter.
NF-κB induction following treatment with (a) MS-275, (b) 17-
AAG, and (c) Combination. SYO-1 cells were grown as monolayer
cultures in 24 well plates and transfected with 0.3μgo fN F - κB
luciferase reporter plasmid. Cells were treated the following day
for 24 hours and lysed with passive lysis buﬀer. Samples were
aliquoted to plates and simultaneously assayed for luminosity by
injection with 50μl/well of LARII reagent and protein quantity by
copper sulfate/bichionic acid assay. Readings for luminosity were
normalized to protein concentration and vehicle control was set
to 1.00. Error bars represent 95% conﬁdence intervals for three
replicate measurements.
and hypocalcemia in clinical trials [45].The HDAC inhibitor
romidepsin has additionally been associated with atrial
ﬁbrillation, tachycardia, and in one case a cardiac sudden
death [46]. Synergism would allow lower doses to be used.
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Figure 5: HDAC3 siRNA knockdown recapitulates the eﬀects HDAC
inhibitors on synovial sarcoma cells. (a) 50nM HDAC3 siRNA
promotes extensive cell death at 24 hours, as shown by staining of
a large inviable cell fraction by 500ng/mL propidium iodide, where
virtuallyallcellsexposedtoequimolarscrambledsiRNAcontrolare
viable. (b) Densitometric quantitation of Western blots for nuclear
RelA, expressed relative to control siRNA transfected cells treated
with vehicle (1.0).
Table 2: Combination of HDAC and NF-κB inhibitors against
synovial sarcoma cells.
Timepoint (hrs)
IC50 average
MS-275 BAY 11-7085 Combination (μM)
(μM) (μM) MS-275 BAY 11
24 4.5 3.5 0.45 1.4
48 0.56 3.4 0.27 0.8
While synergism has been demonstrated by others between
17-AAG and HDAC inhibitors in myelogenous leukemia
cells [10, 28], our study is the ﬁrst to demonstrate that the
orally available agent MS-275 synergizes with 17-AAG. This
is also the ﬁrst demonstration of synergism between Hsp90
and HDAC inhibitors in synovial sarcoma; an often fatal
disease wherein each of these drug classes has recently been
demonstrated to show activity in vitro [6, 16]. Here we have
shown that combinations of the Hsp90 inhibitor 17-AAG8 Sarcoma
and the HDAC inhibitor MS-275 are synergistic, requiring
as little as ninefold less drug to achieve equivalent eﬀects in
vitro against synovial sarcoma models.
Our results provide evidence that synergism between 17-
AAG and MS-275 might be mediated by the prosurvival
NF-κB pathway. Evidence from microarray expression pro-
ﬁling has demonstrated that the NF-κB activator RIPK4
is highly upregulated in synovial sarcoma, and the data
presented here shows that the RelA subunit of NF-κBi s
found in the nucleus of untreated synovial sarcoma cells,
suggesting baseline activation of NF-κB in this malig-
nancy. In addition, the TLE transcriptional corepressor,
which is expressed at extremely high levels in synovial
sarcoma cells [47], forms a complex with HDACs at NF-
κBt a r g e ts i t e s[ 48]. Consistent with a role for NF-κB
in synovial sarcoma growth, we show that a chemical
inhibitor of NF-κB (BAY 11-7085) has in vitro activity
against synovial sarcoma cells as a single agent. Although
additional mechanisms may contribute to the observed
synergy, in separate experiments, we found that neither
17-AAG nor HDAC inhibitors altered the level of SYT-
SSX protein expression, nor are Hsp90 levels or acetylation
status altered by HDAC inhibitor treatment (data not
shown).
In conclusion, the Hsp90 inhibitor 17-AAG and the
HDAC inhibitor MS-275 have synergistic, antiproliferative,
and proapoptotic eﬀects on synovial sarcoma in vitro. 17-
AAG and MS-275 in combination reverse the activation of
NF-κB seen with MS-275 alone, as measured by levels of
the NF-κB inhibitory IκBα complex. Net eﬀects of these
drugs on nuclear levels of the active NF-κB subunit RelA
andonNF-κBluciferasereportertranscriptionareconsistent
with these ﬁndings. The observed eﬀects of MS-275 on
NF-κB can be recapitulated by knocking down HDAC3;
an enzyme which includes RelA as one of its nonhistone
substrates and which is a target of MS-275, depsipeptide,
and several other HDAC inhibitors. In addition, the NF-
κB inhibitor BAY 11-7085 is also synergistic with MS-275.
Agents inhibiting NF-κB in combination with the HDAC
inhibitor MS-275 show promising in vitro activity against
synovial sarcoma; an often-fatal disease of young adults for
which development of truly eﬀective systemic therapies is
needed.
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